Thermo Fisher expands clinical trials capabilities in China

To align with China's effort to encourage drug innovation, the newly expanded Suzhou facility will address the growing demand for drug development supply chain services and focus on high quality primary and secondary packaging solutions for customers and their patients.

Thermo Fisher Scientific, the world leader in serving science, announced an expansion of its integrated clinical trials supply and distribution services network, in Suzhou, China.

The nearly 7,000-square-meter addition in Suzhou offers a full suite of services, including materials storage, packaging and distribution.

The facility will support the growth of clinical trial studies for customers in China and provide emerging biotech companies with the resources to develop and commercialize new drug candidates. 

The expansion adds new Beta Lactam storage, 10°C to 20°C storage and cold chain capacity and increases current storage capacity for temperatures at 15°C to 25°C, 2°C to 8°C and -20°C. With a nearly $4.4 million investment, the Suzhou facility will become Thermo Fisher's largest clinical trials facility in the region. It is also China's only provider of over-encapsulation service, which is widely used in blinding supplies in local and global clinical studies. The facility also adds label printing for high- quality standard and variable print capabilities to increase productivity and improve time to market. 

Expanded facility provides faster access to market for customers conducting clinical trials.

As part of the opening ceremony, a roundtable discussion took place among government officials, industry experts and academic scholars to share insights and discuss trends in drug labeling as well as advances being made in China to improve patient outcomes.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.